# Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

> **NCT04281498** · PHASE2 · COMPLETED · sponsor: **John Mascarenhas** · enrollment: 6 (actual)

## Conditions studied

- Accelerated/Blast-phase Myeloproliferative Neoplasm
- Chronic-phase Myelofibrosis
- IDH2 Mutation

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Enasidenib

## Key facts

- **NCT ID:** NCT04281498
- **Lead sponsor:** John Mascarenhas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-14
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04281498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04281498, "Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04281498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*